BioCryst to Report Third Quarter 2020 Financial Results on November 5
BioCryst Pharmaceuticals (Nasdaq: BCRX) will announce its third quarter 2020 financial results on November 5, 2020. The management team plans to host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide an update on corporate developments.
Investors can join the call at 877-303-8027 for domestic callers and 760-536-5165 for international callers, using conference ID # 3766784. A live webcast will be accessible on the company’s website.
- Upcoming financial results announcement scheduled for November 5, 2020.
- Conference call and webcast planned for discussing financial results and corporate updates.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 3766784. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 3766784.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO™ (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and yellow fever, and BCX9250, an ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When will BioCryst Pharmaceuticals report its third quarter 2020 financial results?
What time is the conference call for BioCryst Pharmaceuticals' financial results?
How can investors access the BioCryst Pharmaceuticals conference call?
Is there a webcast available for BioCryst Pharmaceuticals' financial results?
